AACR, Japanese Cancer Association to host joint session on evolving landscape of gastroesophageal cancers
//
Estimated Read Time:
The recent emergence of biomarkers and novel drugs has significantly altered the treatment and outcomes for patients with gastroesophageal cancer.
The American Association for Cancer Research will convene a joint session with the Japanese Cancer Association (JCA) during the Annual Meeting 2024 to explore the evolving molecular drivers of gastroesophageal cancers and emerging therapies.
The session, Novel Molecular Drivers of Gastroesophageal Cancers and Evolving Biomarker Driven Therapies, will be held Monday, April 8, from 2:30 – 4:30 p.m. PT in Room 29 on the upper level of the San Diego Convention Center.
“Gastroesophageal cancer is a global health problem, with high incidence in East Asia, as well as in the U.S. and Europe,” said Tatsuhiro Shibata, MD, PhD, University of Tokyo, National Cancer Center Research Institute in Japan. “With recent clinical trials and a comprehensive molecular study, this session will be a good opportunity for experts to discuss therapeutic strategy, including molecular targeting and immunotherapy, and molecular diagnosis of this deadly cancer.”
Shibata will serve as co-chair for the session alongside Elena Elimova, MD, MSc, UHN Princess Margaret Cancer Centre in Canada. Other speakers for the session will be Yelena Yuriy Janjigian, MD, Memorial Sloan Kettering Cancer Center in New York, and Kohei Shitara, MD, National Cancer Center Hospital East in Japan.
“It’s an exciting time to address this topic because, over the last five years, we’ve identified numerous biomarkers and developed many new targeted drugs that have improved outcomes for our gastroesophageal cancer patients,” Elimova said. “We’ve been talking about personalized medicine for a very long time, and we are finally now at a time when we can employ a targeted personalized medicine approach to gastroesophageal cancers.”
The AACR and the JCA have a history of collaboration in cancer research. The two associations hold regular special joint conferences that bring basic scientists and clinical researchers from the United States, Japan, and other countries around the world to share the latest developments in colorectal cancer research.
The eighth JCA-AACR Special Joint Conferences on the Molecular Renaissance in Colorectal Cancer is set for June 27-29 (EDT), June 28-30 (JST), 2024, at the Kyoto Tokyu Hotel in Kyoto, Japan.
